Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate efficacy and safety of different doses of AC-3933 in patients with mild to moderate Alzheimer's Disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sunovion

Criteria

Inclusion Criteria:

• Mild to moderate Alzheimer's Disease

• Male or female 55 years or older

• Living with caregiver

• Read, understand and speak English

Exclusion Criteria:

• Need to drive during the study

• Treatment with acetylcholinesterase inhibitors or NMDA antagonist, such as Aricept or Namenda, within 2 weeks of check-up and during the study

• Frequent Smoker

• Frequent Consumer of Caffeine